CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (11)

Name (Synonyms) Correlation
drug1611 non interventional Wiki 0.71
drug1159 Ribavirin Wiki 0.71
drug953 Other drugs Wiki 0.71
drug1358 Telehealth monitoring Wiki 0.71
drug686 Interferon Beta-1B Wiki 0.41
drug889 Nitazoxanide Wiki 0.35
drug715 Ivermectin Wiki 0.25
drug308 Chloroquine Wiki 0.25
drug760 Lopinavir/ritonavir Wiki 0.21
drug505 Favipiravir Wiki 0.21
drug1016 Placebo Wiki 0.05

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D001416 Back Pain NIH 0.71
D017116 Low Back Pain NIH 0.71
D010146 Pain NIH 0.71
D007239 Infection NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19

COVID 19 treatment using Chloroquine with or without Azithromycin, Faviprevir, Nitazoxanide, Ivermectin.

NCT04345419 COVID Drug: Chloroquine Drug: Favipiravir Drug: Nitazoxanide Drug: Ivermectin Drug: Niclosamide Drug: Other drugs

Primary Outcomes

Description: the estimated number of patients with decreased viral load

Measure: Number of patients with decreased viral load

Time: 6 months

2 Niclosamide for Patients With Mild to Moderate Disease From Novel Coronavirus (COVID-19)

This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).

NCT04399356 COVID (SARS-CoV-2) Drug: Niclosamide Drug: Placebo Other: Telehealth monitoring

Primary Outcomes

Description: Oropharangeal swab

Measure: Change in respiratory viral clearance (by PCR)

Time: Day 3 and 10

Secondary Outcomes

Description: Fecal swab

Measure: Fecal viral clearance (by PCR)

Time: Day 14

Description: Oropharngeal swab

Measure: Reduction (change) in viral shedding (by PCR)

Time: Days 1,3,7,10,14

No related HPO nodes (Using clinical trials)